Of note, an inhibitor targeting PGM3, which converts GlcNAc-6-P to GlcNAc-1-P and is thus required for both de novo UDP-GlcNAc synthesis and GlcNAc recycling, showed efficacy in treating gemcitabine-resistant patient-derived xenograft PDA models (Ricciardiello et al., 2020), as well as in breast cancer xenografts (Ricciardiello et al., 2018). The gene discussed is PGM3; the disease is breast carcinoma.